Related Experiment Video

Updated: Feb 4, 2026

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

8.1K

Arrhythmogenic cardiomyopathy: what blood can reveal?

Ilaria Stadiotti1, Giulio Pompilio2, Angela Serena Maione1

  • 1Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Milan, Italy.

Heart Rhythm
|September 30, 2018
PubMed

Insights

Blood analysis offers insights into arrhythmogenic cardiomyopathy (ACM). Researchers are exploring circulating biomarkers for improved noninvasive diagnosis, prognosis, and management of ACM patients.

Area of Science:

  • Cardiology
  • Genetics
  • Biochemistry

Background:

  • Blood, serum, and plasma are key biological fluids for assessing physiological and pathological conditions.
  • Arrhythmogenic cardiomyopathy (ACM) diagnosis often involves detecting germinal genetic mutations in circulating nucleated cells.
  • Various biomarkers, including cytokines, myocardial damage markers, and microRNAs, are investigated for ACM diagnosis and progression monitoring.

Purpose of the Study:

  • To review current knowledge on blood-derived information in arrhythmogenic cardiomyopathy (ACM).
  • To explore the potential of circulating factors for noninvasive ACM diagnosis and prognosis.
  • To consider future directions in utilizing blood biomarkers for ACM patient management.

Main Methods:

  • Literature review of studies on blood biomarkers in arrhythmogenic cardiomyopathy.
  • Analysis of current diagnostic and prognostic markers in ACM.
  • Examination of emerging biomarkers such as microRNAs and inflammatory cytokines.

Main Results:

  • Circulating nucleated cells are established for genetic mutation detection in ACM.
  • Biomarkers like inflammatory cytokines, myocardial damage markers, and microRNAs show promise for ACM diagnosis and monitoring.
  • Blood-derived data offers a potential noninvasive approach to ACM assessment.

Conclusions:

  • Enhanced understanding of circulating factors in ACM can lead to noninvasive diagnostic tools.
  • Biomarker discovery in blood may improve prognosis prediction and patient management strategies for ACM.
  • Future research focusing on blood-based markers could revolutionize ACM care.

Keywords:
Arrhythmogenic right ventricular cardiomyopathyBiomarkersBloodGeneticsHeart failureInflammationPlasmaSerummicroRNA

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
573
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
494
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
545
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
455
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
611
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
357